<?xml version='1.0' encoding='utf-8'?>
<document id="32193358"><sentence text="Insights into Praziquantel metabolism and potential enantiomeric CYP-mediated drug-drug interaction." /><sentence text="The active enantiomer R-Praziquantel (PZQ) shows clinically a lower relative exposure when administered enantiomerically pure compared to a racemic form"><entity charOffset="22-36" id="DDI-PubMed.32193358.s2.e0" text="R-Praziquantel" /><entity charOffset="38-41" id="DDI-PubMed.32193358.s2.e1" text="PZQ" /><pair ddi="false" e1="DDI-PubMed.32193358.s2.e0" e2="DDI-PubMed.32193358.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32193358.s2.e0" e2="DDI-PubMed.32193358.s2.e1" /></sentence><sentence text=" We investigated the hypothesis that enantiomer-enantiomer interactions on CYP enzymes could explain this observation and aimed to further deepen the understanding of PZQ metabolism"><entity charOffset="167-170" id="DDI-PubMed.32193358.s3.e0" text="PZQ" /></sentence><sentence text=" Firstly, in an in vitro metabolite profiling study, the formation of multiple metabolites per CYP, together with an observed interconversion of cis-4'-OH-PZQ to trans-4'-OH-PZQ in human hepatocytes, pointed out the inadequacy of measuring metabolite formation in kinetic studies"><entity charOffset="145-158" id="DDI-PubMed.32193358.s4.e0" text="cis-4'-OH-PZQ" /><entity charOffset="162-177" id="DDI-PubMed.32193358.s4.e1" text="trans-4'-OH-PZQ" /><entity charOffset="155-169" id="DDI-PubMed.32193358.s4.e2" text="PZQ" /><entity charOffset="174-188" id="DDI-PubMed.32193358.s4.e3" text="PZQ" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e0" e2="DDI-PubMed.32193358.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e0" e2="DDI-PubMed.32193358.s4.e2" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e0" e2="DDI-PubMed.32193358.s4.e1" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e0" e2="DDI-PubMed.32193358.s4.e3" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e2" e2="DDI-PubMed.32193358.s4.e2" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e2" e2="DDI-PubMed.32193358.s4.e1" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e2" e2="DDI-PubMed.32193358.s4.e3" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e1" e2="DDI-PubMed.32193358.s4.e1" /><pair ddi="false" e1="DDI-PubMed.32193358.s4.e1" e2="DDI-PubMed.32193358.s4.e3" /></sentence><sentence text=" Thus, a substrate depletion approach to study PZQ enantiomeric interactions was applied"><entity charOffset="47-49" id="DDI-PubMed.32193358.s5.e0" text="PZQ" /></sentence><sentence text=" Secondly, an abundant CYP 3A4 metabolite found in previous studies was structurally characterized" /><sentence text=" Thirdly, substrate depletion methodologies were applied to determine CYP enzyme kinetics of PZQ and to further estimate enantiomer-enantiomer inhibitory parameters"><entity charOffset="93-95" id="DDI-PubMed.32193358.s7.e0" text="PZQ" /></sentence><sentence text=" A competitive inhibition between PZQ enantiomers for CYP2C9, 2C19, 3A4 and 3A5 was revealed"><entity charOffset="34-36" id="DDI-PubMed.32193358.s8.e0" text="PZQ" /></sentence><sentence text=" Analyses considering the clearance of only one or both enantiomers provided comparable enantiomer-enantiomer inhibition estimates" /><sentence text=" To conclude, this paper provides new insights into PZQ metabolic profile to enable a better understanding of enantioselective PK using substrate depletion-based methods"><entity charOffset="52-54" id="DDI-PubMed.32193358.s10.e0" text="PZQ" /></sentence><sentence text=" SIGNIFICANCE STATEMENT: In this study, enantiomer-enantiomer interactions of praziquantel on CYP metabolizing enzymes are investigated via substrate depletion measurement using modelling methods" /><sentence text=" Together with new insights into the praziquantel metabolism, this work provides a novel dataset to understand its pharmacokinetics" /><sentence text="" /></document>